Marija Burek Kamenaric

Dr. Marija Burek Kamenaric

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2020 in Viruses
Verified
Journal Article
Open access
PDF file
MKMarija Burek Kamenaric
Marija Burek Kamenaric
VIVanja Ivković
Vanja Ivković
IVIvana Kovacevic Vojtusek
Ivana Kovacevic Vojtusek
RŽRenata Žunec
Renata Žunec
BK virus (BKV) is a polyomavirus with high seroprevalence in the general population with an unremarkable clinical presentation in healthy people, but a potential for causing serious complications in immunosuppressed transplanted patients. Reactivation or primary infection in kidney allograft recipients may lead to allograft dysfunction and subsequent loss. Currently, there is no widely accepted specific treatment for BKV infection and reduction of immunosuppressive therapy is the mainstay therapy. Given this and the sequential appearance of viruria-viremia-nephropathy, screening and early detection are of utmost importance. There are numerous risk factors associated with BKV infection including genetic factors, among them human leukocyte antigens (HLA) and killer cell immunoglobulin-like receptors (KIR) alleles have been shown to be the strongest so far. Identification of patients at risk for BKV infection would be useful in prevention or early action to reduce morbidity and progression to frank nephropathy. Assessment of risk involving HLA ligands and KIR genotyping of recipients in the pre-transplant or early post-transplant period might be useful in clinical practice. This review summarizes current knowledge of the association between HLA, KIR and BKV infection and potential future directions of research, which might lead to optimal utilization of these genetic markers.

1 February 2017 in Human Immunology
Verified
Journal Article
Closed access
MKMarija Burek Kamenaric
Marija Burek Kamenaric
KJKatarina Stingl Jankovic
Katarina Stingl Jankovic
ZGZorana Grubic
Zorana Grubic
RSRanka Serventi Seiwerth
Ranka Serventi Seiwerth
MMMarija Maskalan
Marija Maskalan
RŽRenata Žunec
Renata Žunec

7 March 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
IVIvana Kovacevic Vojtusek
Ivana Kovacevic Vojtusek
MLMario Laganović
Mario Laganović
MKMarija Burek Kamenaric
Marija Burek Kamenaric
SBStela Bulimbasic
Stela Bulimbasic
SHStela Hrkač
Stela Hrkač
LGLovorka Grgurevic
Lovorka Grgurevic
Background: We have previously shown that metzincin protease ADAMTS-4 accompanies renal fibrogenesis, as it appears in the blood of hemodialysis patients. Methods: Native kidney (NKB) and kidney transplant (TXCI) biopsy samples as well as plasma from patients with various stages of CKD were compared to controls. In paired analysis, 15 TXCI samples were compared with their zero-time biopsies (TX0). Tissues were evaluated and scored (interstitial fibrosis and tubular atrophy (IFTA) for NKB and Banff ci for TXCI). Immunohistochemical (IHC) staining for ADAMTS-4 and BMP-1 was performed. Plasma ADAMTS-4 was detected using ELISA. Results: ADAMTS-4 IHC expression was significantly higher in interstitial compartment (INT) of NKB and TXCI group in peritubular capillaries (PTC) and interstitial stroma (INT). Patients with higher stages of interstitial fibrosis (ci > 1 and IFTA > 1) expressed ADAMTS-4 in INT more frequently in both groups (p = 0.005; p = 0.013; respectively). In paired comparison, TXCI samples expressed ADAMTS-4 in INT and PTC more often than TX0. ADAMTS-4 plasma concentration varied significantly across CKD stages, being highest in CKD 2 and 3 compared to other groups (p = 0.0064). Hemodialysis patients had higher concentrations of ADAMTS-4 compared to peritoneal dialysis (p < 0.00001). Conclusion: ADAMTS-4 might have a significant role in CKD as a potential novel diagnostic indicator.

1 November 2017 in Human Immunology
Verified
Journal Article
Closed access
MKMarija Burek Kamenaric
Marija Burek Kamenaric
MMMarija Maskalan
Marija Maskalan
ZGZorana Grubic
Zorana Grubic
MMMirta Mikulic
Mirta Mikulic
RSRanka Serventi Seiwerth
Ranka Serventi Seiwerth
RŽRenata Žunec
Renata Žunec

1 August 2013 in Human Immunology
Verified
Journal Article
Closed access
MKMarija Burek Kamenaric
Marija Burek Kamenaric
ZGZorana Grubic
Zorana Grubic
KSKatarina Stingl
Katarina Stingl
RŽRenata Žunec
Renata Žunec

30 July 2019 in HLA
Verified
Journal Article
Closed access
PDF file
IVIvana Kovacevic Vojtusek
Ivana Kovacevic Vojtusek
MKMarija Burek Kamenaric
Marija Burek Kamenaric
VIVanja Ivkovic
Vanja Ivkovic
SBStela Bulimbasic
Stela Bulimbasic
IMIvana Marekovic
Ivana Marekovic
RŽRenata Žunec
Renata Žunec